<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03195478</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-672</org_study_id>
    <nct_id>NCT03195478</nct_id>
  </id_info>
  <brief_title>Study of Nivolumab in Combination With Ipilimumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors</brief_title>
  <official_title>A Phase 1/2 Study of Nivolumab (BMS-936558) in Combination With Ipilimumab (BMS-734016) in Chinese Subjects With Previously Treated Metastatic or Recurrent Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Evaluate Safety and Effectiveness of Nivolumab in Combination With Ipilimumab in
      Chinese Patients With Previously Treated Late-Stage Cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1/2 study evaluating safety and pharmacokinetic profile in solid tumor participants
      and preliminary efficacy in metastatic colorectal cancer participants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2017</start_date>
  <completion_date type="Anticipated">November 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 12, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Number and percent of all treated participants that experience Adverse Events (AEs)</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Measured by number of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Number and percent of all treated participants that experience serious adverse events (SAEs)</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Measured by number of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Number and percent of all treated participants that experience AEs leading to discontinuation</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Measured by number of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Number and percent of all treated subjects that experience AEs leading to death</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Measured by number of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Number and percent of participants with clinical laboratory abnormalities</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Measured by number of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blinded independent central review (BICR) assessed Objective Response Rate (ORR)</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Applies to Part 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Measured using serum concentration versus time data. Applies to Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Measured using serum concentration versus time data. Applies to Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the last time of the last quantifiable concentration (AUC[0-T])</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Measured using serum concentration versus time data. Applies to Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUC[TAU])</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Measured using serum concentration versus time data. Applies to Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration achieved at the end of study drug infusion (Ceoinf)</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Measured using serum concentration data. Applies to Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration at the end of dosing interval (Ctrough)</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Measured using serum concentration data. Applies to Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at the end of dosing interval (Ctau)</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Measured using serum concentration data. Applies to Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug Antibody (ADA)</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Measured by immunoassay Applies to Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed ORR</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Applies to Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed and BICR-assessed disease control rate (DCR),</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Applies to Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed and BICR-assessed duration of response (DOR),</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Applies to Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed and BICR-assessed progression-free survival (PFS),</measure>
    <time_frame>Up to 3.2 years</time_frame>
    <description>Applies to Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 4.2 years</time_frame>
    <description>Applies to Part 2</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Nivo/Ipi Combination Therapy A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose of Nivolumab and Ipilimumab on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivo/Ipi Combination Therapy B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivo/Ipi Combination Therapy C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivo/Ipi Combination Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose of Nivolumab on specified days.</description>
    <arm_group_label>Nivo/Ipi Combination Arm D</arm_group_label>
    <arm_group_label>Nivo/Ipi Combination Therapy A</arm_group_label>
    <arm_group_label>Nivo/Ipi Combination Therapy B</arm_group_label>
    <arm_group_label>Nivo/Ipi Combination Therapy C</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified Dose of Ipilimumab on specified days</description>
    <arm_group_label>Nivo/Ipi Combination Arm D</arm_group_label>
    <arm_group_label>Nivo/Ipi Combination Therapy A</arm_group_label>
    <arm_group_label>Nivo/Ipi Combination Therapy B</arm_group_label>
    <arm_group_label>Nivo/Ipi Combination Therapy C</arm_group_label>
    <other_name>BMS-734016</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          1. Mainland Chinese subjects with advanced or recurrent solid tumors.

          2. One prior anti-cancer therapy that did not work or documented refusal to receive
             chemotherapy or biological therapy.

        Exclusion Criteria:

          1. Cancer that has spread to the brain or central nervous system unless it has been
             adequately treated . In addition, either no longer receiving corticosteroids, or on a
             stable or decreasing dose of no more than 10 mg daily prednisone (or equivalent).

          2. Subjects with carcinomatous meningitis

          3. Active, known or suspected autoimmune disease or infection

          4. Positive blood screen for chronic infection of hepatitis B or hepatitis C (HCV
             antibody positive unless HCV RNA is negative)

          5. Prior immuno-oncology therapy

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0015</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0014</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0012</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>155040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0011</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0017</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300222</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0013</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

